Peer-influenced content. Sources you trust. No registration required. This is HCN.

Healthline‘Ozempic Babies’: How Weight Loss Drugs Can Interfere with Birth Control and Boost Fertility

Intersections of GLP-1 Drugs with Fertility and Contraception: Unveiling Unexpected Consequences

Recent discussions have emerged around the unintended pregnancies among users of GLP-1 drugs like Ozempic, raising critical questions about the interaction between weight loss medications and reproductive health. Physicians should be aware of these developments, as they underscore the complexities of managing patients on these medications, particularly concerning fertility and contraceptive efficacy.

Key Points:

  • GLP-1 drugs like Ozempic are linked to unexpected pregnancies among users, despite some being on birth control or having previous infertility issues.
  • Users on social media, particularly TikTok, have shared personal accounts of becoming pregnant while using these medications.
  • The interference with oral contraceptives is attributed to GLP-1 drugs affecting the absorption of pills due to slowed stomach emptying.
  • Weight loss induced by GLP-1 drugs may improve metabolic health and restore ovarian function, thereby enhancing fertility.
  • Dr. Neha Lalani and Dr. Jamie Grifo have observed these phenomena in their clinical practice, highlighting the need for further research.
  • Novo Nordisk advises discontinuing Ozempic at least two months before trying to conceive, due to uncertain effects on pregnancy.
  • An ongoing study aims to explore Wegovy’s safety during human pregnancy, with results expected by August 2027.
  • Physicians should counsel patients on alternative birth control methods when prescribing GLP-1 drugs and closely monitor those planning to conceive.

“This [medications slowing down stomach emptying] causes oral birth control pills to not be absorbed consistently, especially each time the dose of GLP-1/ GIP+ GLP-1 agonists are stepped up. This is resulting in failure of oral birth control pills.”
– Dr. Neha Lalani, Endocrinologist

More in OBGYN

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form